SCHEMBL6539249

SCHEMBL6539249

CC(C)Cn1nc(-c2cc(Cl)c(N)nc2-c2ccccc2)ccc1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.40
KDM4E B2RXH2 2/20 0.38
HSD17B10 Q99714 1/20 0.38
PDE4B Q07343 2/20 0.38
PDE5A O76074 1/20 0.38
PDE3A Q14432 1/20 0.38
MEN1 O00255 5/20 0.37
KMT2A Q03164 5/20 0.37
PDE4A P27815 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
POLB P06746 2/20 0.36
MAPT P10636 2/20 0.36
LMNA P02545 1/20 0.36
STAT3 P40763 1/20 0.36
HTT P42858 1/20 0.35
PRKACA P17612 1/20 0.35
RPS6KB1 P23443 1/20 0.35
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6538523 0.88 TP53 (0.42) TP53PDE4BMEN1KMT2APDE4A
SCHEMBL6538426 0.86 HSD17B10 (0.41) TP53KDM4EHSD17B10PDE5AMEN1
SCHEMBL6538489 0.86 MEN1 (0.49) TP53PDE4BPDE5APDE3AMEN1
SCHEMBL6539046 0.85 TP53 (0.45) TP53KDM4EHSD17B10MEN1KMT2A
SCHEMBL6538480 0.84 HSD17B10 (0.44) TP53HSD17B10PDE4BMEN1KMT2A
SCHEMBL6538926 0.84 POLB (0.39) TP53POLBLMNA
SCHEMBL6539234 0.83 HSD17B10 (0.44) TP53HSD17B10PDE4BMEN1KMT2A
SCHEMBL6538899 0.83 TP53 (0.43) TP53KDM4EHSD17B10MEN1KMT2A
SCHEMBL6538310 0.82 BRD4 (0.42) TP53KDM4EMEN1KMT2AMAPT
SCHEMBL6538514 0.81 POLB (0.39) TP53KDM4EMEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040067955-A1 Pyridazinone compound and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2004-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067955-A1 Pyridazinone compound and pharmaceutical use thereof ADORA1, ADORA2A, P2RX5 TP53 3830/4885KDM4E 3052/4885HSD17B10 2417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.